Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Oct 04, 2022
spot light Spotlight

Personalized Prescription of Chemotherapy Based on Assessment of mRNA Expression of BRCA1, RRM1, ERCC1, TOP1, TOP2α, TUBβ3, TYMS, and GSTP1 Genes in Tumors Compared to Standard Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer
MM Tsyganov et al, J Per Medicine, October 4, 2022

MFS and OS were significantly better in the personalized chemotherapy group compared to the classic chemotherapy group (MFS, 46.22 vs. 22.9 months, p = 0.05; OS, 58.6 vs. 26.9 months, p < 0.0001). Importantly, the best metastasis-free survival rates in the group with personalized ACT were achieved in patients treated with the paclitaxel/carboplatin regimen. Based on an assessment of chemosensitivity gene expression in the tumors, the classical chemotherapy strategy also increased the risk of death (HR = 14.82; 95% CI: 3.33–65.86; p < 0.000) but not metastasis (HR = 1.95; 95% CI: 0.96–3.98; p = 0.06) compared to the group of patients with chemotherapy.

Accelerated approvals hit the target in precision oncology
V Subbiah et al, Nature Medicine, October 3, 2022

Since 1992, there have been 42 accelerated approvals in precision oncology for solid tumors. Accelerated approvals in precision oncology were defined as unique drug–indication pairings that target a specific mutation, such as epidermal growth factor receptor (EGFR), or a population with tumors known to contain a specific mutation, such as mTOR inhibitors for tumors associated with tuberous sclerosis complex (TSC1 and TSC2). Most of these accelerated approvals (86%) were based on overall response rate (ORR), with a median ORR of 53% and a range from 11 to 100%.

Data-driven analysis of a validated risk score for ovarian cancer identifies clinically distinct patterns during follow-up and treatment
S Enroth et al, Comm Medicine, October 3, 2022

Ovarian cancer is the eighth most common cancer among women and due to late detection prognosis is poor with an overall 5-year survival of 30–50%. Novel biomarkers are needed to reduce diagnostic surgery and enable detection of early-stage cancer by population screening. We have previously developed a risk score based on an 11-biomarker plasma protein assay to distinguish benign tumors (cysts) from malignant ovarian cancer in women with adnexal ovarian mass.

To prevent unnecessary biopsies, scientists train an AI model to predict breast cancer risk from MRI scans
JW Lee, Stat News, October 3, 2022

In a new paper, Witowski and his colleagues at NYU and Jagiellonian University in Poland present an artificial intelligence tool that can predict the probability of breast cancer in MRI scans as well as a panel of board-certified radiologists. In a retrospective analysis, it was also capable of reducing unnecessary biopsies by up to 20% for patients whose MRIs show suspicious lesions that might warrant a biopsy, officially known as BI-RADS category 4 lesions.

news Latest News and Publications
A Methylation-Based Prognostic Signature in Stage II Colorectal Patients: Considerations for Clinical Adoption. External Web Site Icon
Romesser Paul B et al. Journal of the National Cancer Institute 2022 9
Analysis of rare disruptive germline mutations in 2,135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes. External Web Site Icon
Loveday C et al. Annals of oncology : official journal of the European Society for Medical Oncology 2022
Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real World Data. External Web Site Icon
Iyer Pritish et al. JNCI cancer spectrum 2022
Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer. External Web Site Icon
McCarthy Anne Marie et al. Breast cancer research and treatment 2022
Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer. External Web Site Icon
Yuan Zhen et al. Medical science monitor : international medical journal of experimental and clinical research 2022 28e937757
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases. External Web Site Icon
Lakeman Inge M M et al. Journal of medical genetics 2022
Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. External Web Site Icon
Whitworth Pat W et al. JAMA network open 2022 5(9) e2232787
Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. External Web Site Icon
Tarawneh Thomas S et al. Cancers 2022 14(18)
Current Screening Strategies for Pancreatic Cancer. External Web Site Icon
Vanek Petr et al. Biomedicines 2022 10(9)
Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? External Web Site Icon
Zhou Charlie D et al. Cancer prevention research (Philadelphia, Pa.) 2022 OF1-OF11
Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer? External Web Site Icon
Bilani Nadeem et al. Breast (Edinburgh, Scotland) 2022 6649-53
Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study. External Web Site Icon
Takada Kohichi et al. Frontiers in oncology 2022 12988527
Familial Pancreatic Cancer. External Web Site Icon
Saba Helena et al. Gastroenterology clinics of North America 2022 51(3) 561-575
Hereditary Breast and Ovarian Cancer Week in Michigan: September 25 – October 1, 2022 External Web Site Icon
Gretchen Whitmer, governor of Michigan proclaims September 25 - October 1, 2022, as Hereditary Breast and Ovarian Cancer Week in Michigan.
Implementation and outcome evaluations of a multi-site improvement program in cancer genetics. External Web Site Icon
Bednar Erica M et al. Journal of genetic counseling 2022
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing. External Web Site Icon
Lee Jeonghyo et al. Journal of pathology and translational medicine 2022 56(5) 249-259
Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing. External Web Site Icon
Llorin Hannah et al. Cancer genetics 2022 268-26922-27
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. External Web Site Icon
Vliek Sonja B et al. European journal of cancer (Oxford, England : 1990) 2022 175169-179
Ultrasonography screening in children and adolescents who have one parent with familial non-medullary thyroid carcinoma. External Web Site Icon
Rosario Pedro W et al. Journal of paediatrics and child health 2022
Usefulness of Genetic Aberration and Shorter Telomere Length in Myelodysplastic Syndrome: A Pilot Study. External Web Site Icon
Park Hee Sue et al. Laboratory medicine 2022


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.